CEOs, Senior Executives Outline Growth Strategies and Plans at the Virtual DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies provide the latest major news from their companies impacting the bio/pharmaceutical manufacturing value chain: manufacturing expansions, mergers and acquisitions, and other key updates.

News from across the bio/pharmaceutical manufacturing value chain

What is the latest news impacting the bio/pharmaceutical manufacturing value chain? As part of Virtual DCAT Week, held July 12-16, 2021, select DCAT Member Companies made major news announcements highlighting manufacturing expansions, mergers and acquisitions (M&A)/M&A integration, and other key strategic updates.

DCAT Week is the premier global event for companies engaged in the bio/pharmaceutical manufacturing value chain and is organized by the Drug, Chemical & Associated Technologies Association (DCAT), a global business-development association. In 2021, DCAT Week was held virtually.

CEOs and senior executives made video announcements to outline their companies’ news. Participating companies included: Boehringer Ingelheim, Cytiva, Catalent, EuroAPI (the planned spinoff from Sanofi of a new European API manufacturing company), Evonik, Lonza, Samsung Biologics, Thermo Fisher Scientific, and WuXi STA. The full listing of companies and the focus of their announcements may be found in the table below.

The video announcements are available for viewing exclusively to DCAT Member Companies, and instructions on how to access the videos may be found here.

Participating companies were selected by the DCAT Member Company Announcement Oversight Task Force based on meeting content and presentation criteria.

Virtual DCAT Member Company Announcement Forum:
Announcements From Across the Global Bio/Pharmaceutical Manufacturing Value Chain

Aceto: Gilles Cottier, CEO 
Acquisition and integration of five companies to add to its manufacturing footprint in fine chemicals and life sciences
Ajinomoto Bio-Pharma Services: Dr. Mark Cassidy, CEO & President, Ajinomoto Bio-Pharma Services Europe
Global expansions in small-molecule API development and manufacturing (including HPAPIs, oligonucleotides and continuous flow chemistry) and fill–finish capacity
Asymchem: Elut Hsu, President & Senior Vice President, Business Development
Investments in China for two new small-molecule API development and manufacturing facilities
Boehringer Ingelheim: Dr. Christian Eckermann, Senior Vice President, Biopharma Austria
Update on its new EUR 700-M ($829-M) biomanufacturing facility in Vienna
Carbogen Amcis: Mark Griffiths, Dishman Carbogen Amcis Group CEO
Updates on its new small-molecule API manufacturing facility in Switzerland and new formulation and fill–finish facility in France
Catalent: Karen Flynn, President, Biologics & Chief Commercial Officer
Updates on $380-M-plus manufacturing expansions in biologics, cell & gene therapies, drug products, and cold-chain and cryogenic capabilities
Cytiva: Emmanuel Ligner, Danaher Group Executive & President and CEO, Cytiva
Acquisition and integration of three companies to support digital bioprocessing, lipid nanoparticle technologies, and small-scale aseptic filling
DSM Nutritional Products: Kelsey Achenbach, Global Segment Director, Pharma & Medical Nutrition
Formed a new strategic partnership to extend its pharmaceutical offering to include cannabinoid APIs
Evonik: Dr. Stefan Randl, Vice President, Research, Development & Innovation, Nutrition & Care, Health Care
Update on expansion of small-molecule API manufacturing sites in Germany
Frontida BioPharm: Eric Kinzler, Ph.D., Study Director, testing services for Abuse-Deterrent Formulations
Investment to increase capabilities in abuse-deterrent formulations and development
Gerresheimer: Niels Düring, Global Executive Vice President, Primary Packaging Plastics
US expansion of pharma plastic packaging production capacity
Helsinn Advanced Synthesis: Waldo Mossi, General Manager
Lab and manufacturing expansion for HPAPIs
LGM Pharma: Prasad Raje, CEO
Update on integration of acquisition of a drug-product CDMO
Lonza: Christian Dowdeswell, Head of Commercial Development, Small Molecules
Global expansions in: (1) small-molecule API development and manufacturing (including HPAPIs); (2) large-scale biomanufacturing (CHF 650 M [$703 M] investment); and (3) cell & gene therapy manufacturing
Ortec: Christopher Brotherton, President
New GMP chemical manufacturing facility in Ireland
PharmaBlock: Jing Li, Ph.D., Senior Vice President
Combined $155 M facilities expansion in China for small-molecule API and drug-product manufacturing
Polpharma: Shlomo Gang, General Director, Polpharma API
Small-molecule API manufacturing expansion (including HPAPIs) and cryogenic capabilities
Rondo-Pak: Bob Reilley, President & COO
Equipment additions for packaging (folding cartons)
Samsung Biologics: Segang Park, Vice President, Team Leader, Engineering Project Management, EPCV
Update on new $1.47-Bn biomanufacturing facility in Incheon, South Korea
Sanofi US SAIS/EuroAPI: Karl Rotthier, CEO, EuroAPI
Update on planned spin-off of new European API manufacturing company from Sanofi
Sterling Pharma Solutions: Kevin Cook, CEO
Acquisition and integration of a CDMO specializing in HPAPIs and bioconjugation and acquisition of US small-molecule API manufacturing site
Stevanato Group: Mauro Stocchi, Chief Business Officer
$145-M investment for new US manufacturing facility for containment solutions for aseptic manufacturing
Thermo Fisher Scientific: Leon Wyszkowski, President, Commercial Operations, Pharma Services
Global expansions in development and manufacturing of biologics, cell & gene therapies, and drug products and expansion of clinical supply-chain capabilities
Valsynthese: Mara Guzzetti, Ph.D., Senior Executive Vice President, Fine Chemicals
New production hydrogenation facility, upgrade of pilot production, and new kilo laboratory for hazardous chemistry
WuXi STA: Yu Lu, Vice President, Business Operations, & Jinling Chen, Senior Vice President, Drug Product Division
Global expansions in small-molecule API manufacturing (including HPAPIs, oligonucleotides, peptides) and drug-product manufacturing

Leave a Reply

Your email address will not be published.

Recent Feature Articles

CDMO M&A: What Are The Important Moves?

As we near the fourth quarter of 2022, what have been the key mergers and acquisitions thus far in the CDMO/CMO sector and what new CDMOs/CMOs have entered the market? DCAT Value Chain Insights takes a look.

Industry Radar: Impact Factors for Sourcing

How is current market volatility, led by inflationary pressures, supply-chain disruptions, and geopolitical uncertainty, impacting sourcing and supply decisions? A look at what is on the industry’s radar.

EU Energy and Supply: What Will Happen Next?

The European Commission proposed this week an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a severe mismatch between energy demand and supply. What is in the proposal?

Industry Radar: Top 10 To Watch For Rest of 2022

What are the key issues and trends in play for the rest of 2022? From energy supply to inflationary pressures to new bio/pharmaceutical products launches, DCAT Value Chain Insights takes an inside look of what may be next.